Dr. Nathan Jorgensen brings a comprehensive background of buy-side, sell-side, consulting, and scientific experience to his new role at Vor. At QIA, the sovereign wealth fund of the State of Qatar, he spearheaded biotechnology and pharmaceutical investment efforts, which included opportunities in public, private, and specialty investments. Prior to joining QIA, he led investments in therapeutics at Calamos, a growth-focused public equity investment firm with $25 billion of assets under management. Before joining Calamos, Dr. Jorgensen covered mid- and large-cap biotech companies at the investment bank Stifel Nicolaus. Prior to working on Wall Street, Dr. Jorgensen investigated the pathobiology of Parkinson’s disease at the Columbia University Medical Center as a post-doctoral scientist. He earned an MBA from the Johnson School at Cornell University and a PhD from the University of Minnesota.